Shanghai-based clinical-stage biopharmaceutical company Cytovant has raised $23.5 million in a new funding round, per an announcement on Friday. The round was led by global financial services company BNH Investment, a South Korean VC firm that focuses primarily on bio & healthcare industries.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
